v3.25.2
Segment Information - Schedule of Reportable Segment Net Loss, Including Significant Expense Categories Attributable to Company's Reportable Segment (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Collaboration agreements $ 250 $ 1,073 $ 250 $ 53,477
Operating expenses:        
Total research and development costs 14,283 30,075 34,553 63,045
Total general and administrative costs 6,029 8,317 13,681 16,935
Restructuring cost 3,384 0 6,649 0
Total operating expenses 23,696 38,392 54,883 79,980
Gain on sale of technology and other assets 5,666 0 5,666 0
Loss from operations (17,780) (37,319) (48,967) (26,503)
Other income, net 1,284 2,871 2,798 5,846
Income tax expense (248) (326) (618) (955)
Net loss (16,744) (34,774) (46,787) (21,612)
Operating Segments        
Segment Reporting Information [Line Items]        
Collaboration agreements 250 1,073 250 53,477
Operating expenses:        
Total research and development costs 14,283 30,075 34,553 63,045
Personnel related costs 2,944 5,220 7,522 10,939
Other general administrative costs 3,085 3,097 6,159 5,996
Total general and administrative costs 6,029 8,317 13,681 16,935
Restructuring cost 3,384 0 6,649 0
Total operating expenses 23,696 38,392 54,883 79,980
Gain on sale of technology and other assets 5,666 0 5,666 0
Loss from operations (17,780) (37,319) (48,967) (26,503)
Other income, net 1,284 2,871 2,798 5,846
Income tax expense (248) (326) (618) (955)
Net loss (16,744) (34,774) (46,787) (21,612)
Operating Segments | Discovery Costs        
Operating expenses:        
Direct external costs 259 1,398 957 3,124
Laboratory supplies and research materials 90 959 344 1,957
Personnel related costs 243 3,232 1,750 6,418
Facilities related costs 145 393 503 798
Other costs 65 842 643 1,754
Operating Segments | Development Costs        
Operating expenses:        
Personnel related costs 5,070 9,186 13,233 18,845
Facilities related costs 233 213 480 421
Other costs 695 1,186 1,584 2,618
Debiopharm development cost reimbursement (1,413) (880) (2,682) (1,380)
R&D tax credits (71) (260) (206) (554)
Operating Segments | Development Costs | Camonsertib Program        
Operating expenses:        
Direct external costs 1,848 3,961 4,114 7,941
Operating Segments | Development Costs | Lunresertib Program        
Operating expenses:        
Direct external costs 3,999 7,660 8,274 15,767
Operating Segments | Development Costs | RP-1664 Program        
Operating expenses:        
Direct external costs 1,579 1,412 2,921 3,008
Operating Segments | Development Costs | RP-3467 and Pol Program        
Operating expenses:        
Direct external costs $ 1,541 $ 773 $ 2,638 $ 2,328